Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax compare to intensive chemotherapy (IC) in patients who are ‘fit’ or ‘unfit’ for IC. We compared outcomes of older patients with ne...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Maiti, Abhishek, Qiao, Wei, Sasaki, Koji, Ravandi, Farhad, Kadia, Tapan M., Jabbour, Elias J., Daver, Naval G., Borthakur, Gautam, Garcia-Manero, Guillermo, Pierce, Sherry A., Montalbano, Kathryn S., Pemmaraju, Naveen, Naqvi, Kiran, Ohanian, Maro, Short, Nicholas J., Alvarado, Yesid, Takahashi, Koichi, Yilmaz, Musa, Jain, Nitin, Kornblau, Steven M., Andreeff, Michael, Bose, Prithviraj, Ferrajoli, Alessandra, Issa, Ghayas C., Masarova, Lucia, Thompson, Philip A., Rausch, Caitlin R., Ning, Jing, Kantarjian, Hagop M., DiNardo, Courtney D., Konopleva, Marina Y.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128145/
https://ncbi.nlm.nih.gov/pubmed/33264443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.26061
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados